Mainstream

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Post Contentorka, abbvRead More

You might also be interested in reading Judge Rules Against Most of DCG’s Motion to Dismiss NYAG’s Civil Securities Fraud Suit.

September 17, 2025
In Mainstream